{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T11:15:45Z","timestamp":1769598945840,"version":"3.49.0"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2023,3,9]],"date-time":"2023-03-09T00:00:00Z","timestamp":1678320000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare","doi-asserted-by":"publisher","award":["21AA2007"],"award-info":[{"award-number":["21AA2007"]}],"id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare","doi-asserted-by":"publisher","award":["22AA2003"],"award-info":[{"award-number":["22AA2003"]}],"id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","award":["20H03907"],"award-info":[{"award-number":["20H03907"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","award":["21K08294"],"award-info":[{"award-number":["21K08294"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,6,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Intravenous immunoglobulin (IVIg) has been reported to be an effective treatment for bullous pemphigoid. However, the impact of IVIg approval on real-world outcomes remains unclear.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To investigate the effect of IVIg approval on patients with bullous pemphigoid using a national inpatient database.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Using the Japanese Diagnosis Procedure Combination database, we identified 14 229 patients admitted to hospital for bullous pemphigoid and treated with systemic corticosteroids between July 2010 and March 2020. We conducted an interrupted time-series analysis to compare in-hospital mortality and morbidity between the patients admitted before and after the approval of reimbursement of IVIg for bullous pemphigoid in the Japanese universal health insurance system in November 2015.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>In-hospital mortality was 5.5% before and 4.5% after the approval of IVIg reimbursement. After the IVIg approval, 18% of the patients were treated with IVIg. Based on the interrupted time-series analysis, in-hospital mortality significantly decreased at the time of approval [\u20131.2%, 95% confidence interval (CI) \u20132.0 to \u20130.3, P = 0.009] and a downward trend was observed after the approval (\u20130.4% annual rate, 95% CI \u20130.7 to \u20130.1, P = 0.005). In-hospital morbidity also demonstrated a downward trend after the approval.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>IVIg approval is associated with lower in-hospital mortality and morbidity in inpatients with bullous pemphigoid.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ced\/llad086","type":"journal-article","created":{"date-parts":[[2023,3,9]],"date-time":"2023-03-09T09:24:17Z","timestamp":1678353857000},"page":"667-673","source":"Crossref","is-referenced-by-count":1,"title":["Trends in mortality and morbidity in patients with bullous pemphigoid before and after approval of intravenous immunoglobulin in Japan: an interrupted time-series analysis"],"prefix":"10.1093","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2549-6690","authenticated-orcid":false,"given":"Hideaki","family":"Miyachi","sequence":"first","affiliation":[{"name":"Department of Dermatology, Graduate School of Medicine, Chiba University , Chiba , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takaaki","family":"Konishi","sequence":"additional","affiliation":[{"name":"Department of Clinical Epidemiology and Health Economics, School of Public Health, The University of Tokyo , Tokyo , Japan"},{"name":"Science, Technology, and Innovation Governance Education and Research Program, Graduate School of Public Policy, The University of Tokyo , Tokyo , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yohei","family":"Hashimoto","sequence":"additional","affiliation":[{"name":"Department of Clinical Epidemiology and Health Economics, School of Public Health, The University of Tokyo , Tokyo , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroki","family":"Matsui","sequence":"additional","affiliation":[{"name":"Department of Clinical Epidemiology and Health Economics, School of Public Health, The University of Tokyo , Tokyo , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiyohide","family":"Fushimi","sequence":"additional","affiliation":[{"name":"Department of Health Policy and Informatics, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University , Tokyo , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Inozume","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Graduate School of Medicine, Chiba University , Chiba , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Matsue","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Graduate School of Medicine, Chiba University , Chiba , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideo","family":"Yasunaga","sequence":"additional","affiliation":[{"name":"Department of Clinical Epidemiology and Health Economics, School of Public Health, The University of Tokyo , Tokyo , Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2023,3,9]]},"reference":[{"key":"2023100918461957100_llad086-B1","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/S0140-6736(12)61140-4","article-title":"Pemphigoid diseases","volume":"381","author":"Schmidt","year":"2013","journal-title":"Lancet"},{"key":"2023100918461957100_llad086-B2","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1111\/1346-8138.15111","article-title":"Japanese guidelines for the management of pemphigoid (including epidermolysis bullosa acquisita)","volume":"46","author":"Ujiie","year":"2019","journal-title":"J Dermatol"},{"key":"2023100918461957100_llad086-B3","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1111\/j.1365-2133.2005.06662.x","article-title":"Annual incidence and mortality of bullous pemphigoid in the Grampian Region of North-east Scotland","volume":"153","author":"Gudi","year":"2005","journal-title":"Br J Dermatol"},{"key":"2023100918461957100_llad086-B4","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1111\/j.1365-2133.2009.09300.x","article-title":"Incidence of bullous pemphigoid and pemphigus in Switzerland: a 2-year prospective study","volume":"161","author":"Marazza","year":"2009","journal-title":"Br J Dermatol"},{"key":"2023100918461957100_llad086-B5","first-page":"434","article-title":"Prospective analysis of the incidence of autoimmune bullous disorders in Lower Franconia, Germany","volume":"7","author":"Bertram","year":"2009","journal-title":"J Dtsch Dermatol Ges"},{"key":"2023100918461957100_llad086-B6","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1038\/jid.2012.35","article-title":"Incidence and mortality of bullous pemphigoid in France","volume":"132","author":"Joly","year":"2012","journal-title":"J Invest Dermatol"},{"key":"2023100918461957100_llad086-B7","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.a180","article-title":"Bullous pemphigoid and pemphigus vulgaris \u2013 incidence and mortality in the UK: population based cohort study","volume":"337","author":"Langan","year":"2008","journal-title":"BMJ"},{"key":"2023100918461957100_llad086-B8","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.jaad.2014.02.030","article-title":"Incidence of bullous pemphigoid and mortality of patients with bullous pemphigoid in Olmsted County, Minnesota, 1960 through 2009","volume":"71","author":"Brick","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"2023100918461957100_llad086-B9","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1056\/NEJMoa011592","article-title":"A comparison of oral and topical corticosteroids in patients with bullous pemphigoid","volume":"346","author":"Joly","year":"2002","journal-title":"N Engl J Med"},{"key":"2023100918461957100_llad086-B10","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s40257-020-00513-3","article-title":"A review comparing international guidelines for the management of bullous pemphigoid, pemphigoid gestationis, mucous membrane pemphigoid, and epidermolysis bullosa acquisita","volume":"21","author":"Patel","year":"2020","journal-title":"Am J Clin Dermatol"},{"key":"2023100918461957100_llad086-B11","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1111\/jdv.18220","article-title":"Updated S2 K guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology (EADV)","volume":"36","author":"Borradori","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2023100918461957100_llad086-B12","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/S0140-6736(17)30560-3","article-title":"Doxycycline versus prednisolone as an initial treatment strategy for bullous pemphigoid: a pragmatic, non-inferiority, randomised controlled trial","volume":"389","author":"Williams","year":"2017","journal-title":"Lancet"},{"key":"2023100918461957100_llad086-B13","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jdermsci.2016.11.003","article-title":"A randomized double-blind trial of intravenous immunoglobulin for bullous pemphigoid","volume":"85","author":"Amagai","year":"2017","journal-title":"J Dermatol Sci"},{"key":"2023100918461957100_llad086-B14","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/S0140-6736(84)92565-0","article-title":"Plasma exchange in bullous pemphigoid","volume":"324","author":"Roujeau","year":"1984","journal-title":"Lancet"},{"key":"2023100918461957100_llad086-B15","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1001\/archderm.1993.01680220061016","article-title":"Controlled trial of azathioprine and plasma exchange in addition to prednisolone in the treatment of bullous pemphigoid","volume":"129","author":"Guillaume","year":"1993","journal-title":"Arch Dermatol"},{"key":"2023100918461957100_llad086-B16","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.h2750","article-title":"Regression based quasi-experimental approach when randomisation is not an option: interrupted time series analysis","volume":"350","author":"Kontopantelis","year":"2015","journal-title":"BMJ"},{"key":"2023100918461957100_llad086-B17","first-page":"348","article-title":"Interrupted time series regression for the evaluation of public health interventions: a tutorial","volume":"46","author":"Bernal","year":"2017","journal-title":"Int J Epidemiol"},{"key":"2023100918461957100_llad086-B18","doi-asserted-by":"crossref","first-page":"76","DOI":"10.37737\/ace.1.3_76","article-title":"Real World Data in Japan: Chapter II The diagnosis procedure combination database","volume":"1","author":"Yasunaga","year":"2019","journal-title":"Ann Clin Epidemiol"},{"key":"2023100918461957100_llad086-B19","doi-asserted-by":"crossref","first-page":"867","DOI":"10.2471\/BLT.07.045120","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"85","author":"von Elm","year":"2007","journal-title":"Bull World Health Organ"},{"key":"2023100918461957100_llad086-B20","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.je.2016.09.009","article-title":"Validity of diagnoses, procedures, and laboratory data in Japanese administrative data","volume":"27","author":"Yamana","year":"2017","journal-title":"J Epidemiol"},{"key":"2023100918461957100_llad086-B21","doi-asserted-by":"crossref","DOI":"10.1016\/j.canep.2021.102016","article-title":"Validity of initial cancer diagnoses in the Diagnosis Procedure Combination data in Japan","volume":"74","author":"Shigemi","year":"2021","journal-title":"Cancer Epidemiol"},{"key":"2023100918461957100_llad086-B22","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1186\/s12913-021-07135-3","article-title":"Validity of diagnoses and procedures in Japanese dental claims data","volume":"21","author":"Ono","year":"2021","journal-title":"BMC Health Serv Res"},{"key":"2023100918461957100_llad086-B23","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1007\/s00595-022-02521-8","article-title":"Validity of operative information in Japanese administrative data: a chart review-based analysis of 1221 cases at a single institution","volume":"52","author":"Konishi","year":"2022","journal-title":"Surg Today"},{"key":"2023100918461957100_llad086-B24","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s40257-019-00443-9","article-title":"Association of early systemic corticosteroid therapy with mortality in patients with Stevens-Johnson syndrome or toxic epidermal necrolysis: a retrospective cohort study using a nationwide claims database","volume":"20","author":"Morita","year":"2019","journal-title":"Am J Clin Dermatol"},{"key":"2023100918461957100_llad086-B25","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1016\/j.jaad.2021.06.008","article-title":"Treatments and outcomes of generalized pustular psoriasis: a cohort of 1516 patients in a nationwide inpatient database in Japan","volume":"86","author":"Miyachi","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"2023100918461957100_llad086-B26","first-page":"21","article-title":"Association between psoriasis and short-term outcomes of acute myocardial infarction: a matched-pair cohort study using a nationwide inpatient database in Japan","volume-title":"JAAD Int","author":"Miyachi","year":"2022"},{"key":"2023100918461957100_llad086-B27","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1111\/1346-8138.16641","article-title":"Clinical course and outcomes of pemphigus vulgaris and foliaceus: a retrospective study using a nationwide database in Japan","volume":"50","author":"Miyachi","year":"2023","journal-title":"J Dermatol"},{"key":"2023100918461957100_llad086-B28","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1111\/bjd.14172","article-title":"Validation of database search strategies for the epidemiological study of pemphigus and pemphigoid","volume":"174","author":"Hsu","year":"2016","journal-title":"Br J Dermatol"},{"key":"2023100918461957100_llad086-B29","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"key":"2023100918461957100_llad086-B30","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1093\/aje\/kwq433","article-title":"Updating and validating the Charlson Comorbidity Index and score for risk adjustment in hospital discharge abstracts using data from 6 countries","volume":"173","author":"Quan","year":"2011","journal-title":"Am J Epidemiol"},{"key":"2023100918461957100_llad086-B31","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1097\/MLR.0000000000000471","article-title":"The best use of the Charlson Comorbidity Index with electronic health care database to predict mortality","volume":"54","author":"Bannay","year":"2016","journal-title":"Med Care"},{"key":"2023100918461957100_llad086-B32","article-title":"Effect of restricting the legal supply of prescription opioids on buying through online illicit marketplaces: interrupted time series analysis","volume":"361","author":"Martin","year":"2018","journal-title":"BMJ"},{"key":"2023100918461957100_llad086-B33","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1017\/ice.2020.427","article-title":"Impact of national guidelines for antimicrobial stewardship to reduce antibiotic use in upper respiratory tract infection and gastroenteritis","volume":"42","author":"Sato","year":"2021","journal-title":"Infect Control Hosp Epidemiol"},{"key":"2023100918461957100_llad086-B34","doi-asserted-by":"crossref","DOI":"10.1002\/ajh.24644","article-title":"Association of immune globulin intravenous and thromboembolic adverse events","volume":"92","author":"Ovanesov","year":"2017","journal-title":"Am J Hematol"},{"key":"2023100918461957100_llad086-B35","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.tmrv.2013.05.004","article-title":"Adverse effects of human immunoglobulin therapy","volume":"27","author":"Stiehm","year":"2013","journal-title":"Transfus Med Rev"},{"key":"2023100918461957100_llad086-B36","doi-asserted-by":"crossref","first-page":"197","DOI":"10.2147\/CLEP.S176723","article-title":"Sample size and power considerations for ordinary least squares interrupted time series analysis: a simulation study","volume":"11","author":"Hawley","year":"2019","journal-title":"Clin Epidemiol"},{"key":"2023100918461957100_llad086-B37","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1001\/jamadermatol.2018.4556","article-title":"Association of dipeptidyl peptidase 4 inhibitor use with risk of bullous pemphigoid in patients with diabetes","volume":"155","author":"Lee","year":"2019","journal-title":"JAMA Dermatol"},{"key":"2023100918461957100_llad086-B38","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s12902-021-00689-7","article-title":"The association of bullous pemphigoid with dipeptidyl-peptidase 4 inhibitors: a ten-year prospective observational study","volume":"21","author":"Lambadiari","year":"2021","journal-title":"BMC Endocr Disord"},{"key":"2023100918461957100_llad086-B39","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1016\/j.jid.2016.06.622","article-title":"Autoantibody profile differentiates between inflammatory and noninflammatory bullous pemphigoid","volume":"136","author":"Izumi","year":"2016","journal-title":"J Invest Dermatol"},{"key":"2023100918461957100_llad086-B40","doi-asserted-by":"crossref","first-page":"32","DOI":"10.2340\/00015555-2456","article-title":"Bullous pemphigoid: validation of the national patient register in two counties in Sweden, 2001 to 2012","volume":"97","author":"Gronhagen","year":"2017","journal-title":"Acta Derm Venereol"}],"container-title":["Clinical and Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ced\/advance-article-pdf\/doi\/10.1093\/ced\/llad086\/50340319\/llad086.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/48\/6\/667\/51961798\/llad086.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/48\/6\/667\/51961798\/llad086.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T18:52:37Z","timestamp":1696877557000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ced\/article\/48\/6\/667\/7073694"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,9]]},"references-count":40,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,3,9]]},"published-print":{"date-parts":[[2023,6,5]]}},"URL":"https:\/\/doi.org\/10.1093\/ced\/llad086","relation":{},"ISSN":["0307-6938","1365-2230"],"issn-type":[{"value":"0307-6938","type":"print"},{"value":"1365-2230","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,6]]},"published":{"date-parts":[[2023,3,9]]}}}